Favipiravir | Inhibitor of viral RNA-dependent RNA polymerase
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 10 mg | $40.00 | ||
| 50 mg | $140.00 |
Favipiravir (259793-96-9) is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7
References/Citations:
1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977
2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235
3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517
4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981
5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446
6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58
7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Favipiravir (259793-96-9) is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7
References/Citations:
1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977
2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235
3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517
4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981
5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446
6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58
7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657
Related products
-
Rucaparib phosphate | PARP1 inhibitor
From $70.00CAS:459868-92-9Catalog Number:10-3321Activity:PARP1 inhibitorChemical Name:8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-oneAlternate Name:AG-14699; PF01367338Molecular Weight:421.36Molecular Formula:C19H18FN3O • H3PO4Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.Shipping Code:RT -
ML335 | TREK-1,2 activator
From $55.00CAS:825658-06-8Catalog Number:10-3648Activity:TREK-1,2 activatorChemical Name:N-(2,4-Dichlorobenzyl)-4-(methylsulfonamido)benzamideMolecular Weight:373.25Molecular Formula:C15H14Cl2N2O3SSolubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 20 mg/ml with warming).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.Shipping Code:RT -
Imiquimod | TLR7 Agonist
From $30.00CAS:99011-02-6Catalog Number:10-4230Alternate Name:R837Activity:TLR7 agonistChemical Name:1-(2-Methylpropyl)imidazo[4,5-c]quinolin-4-amineMolecular Weight:240.30Molecular Formula:C14H16N4Solubility:Soluble in DMSO (2 mg/ml with warming)Physical Properties:White solidPurity:>98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
